Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-08-05

FDA Approved: CARBAGLU — Supplemental Application (Recordati Rare Diseases)

View source ↗

Summary

The FDA approved a supplemental application for CARBAGLU (carbaglumic acid) from Recordati Rare Diseases, extending its approved use for patients with hyperammo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carbaglu (carglumic acid)

Snippet

SUPPL AP for CARBAGLU (CARGLUMIC ACID)